Primary PCL is a distinct clinic-pathologic entity with different cytogenetic and molecular findings. The clinical course is aggressive with short remissions and survival duration. The diagnosis is based upon the percentage and absolute number of plasma cells in the peripheral blood. The new document proposes that the thresholds for diagnosis be reexamined and consensus recommendations are made for diagnosis and treatment, as well as, response and progression criteria.
The IDIBAPS team Hematological oncology, led by Dr. Francisco Cervantes, is an international reference in the field of hematological oncology. Their work covers clinical, applied and basic research. With 41 Original articles published in 2011, and an average IF of 8.7 points per article, it is one of the most productive research teams at IDIBAPS.